The funding program is aimed at researchers working in the field of translational cancer research at universities, non-academic research institutions, and research departments in related sectors.
The expected outcome of the call is to improve the efficacy of the detection, diagnosis, prognosis, and treatment of cancers through the development of novel approaches based on a better understanding of cancer epigenetics. The specific objectives of this funding opportunity are to stimulate new partnerships between researchers and clinicians and support original, high-quality projects with significant clinical impact.
Funding period and funding amount
The maximum funding period is 36 months.
The requirements and specifications for the FWF programs Principal Investigator Projects or Clinical Research apply.
- Decided by the Scientific Board based on a recommendation of the Call Secretariat
- Expected in May 2024
Each proposal must involve a minimum of 3 and a maximum of 6 researchers from at least 3 different participating TRANSCAN-3 partner countries. A joint proposal must be submitted by the project coordinator to the central Call Secretariat.
Details can be found in the call text published on the TRANSCAN website.
In addition to the submission to the Call Secretariat, the proposal must also be uploaded to elane, the FWF's application portal, before the specified deadline to ensure eligibility. Details can be found in the document Guidelines for Applicants, also available on the TRANSCAN website.
This program is subject to a two-stage application procedure.
Deadline for submission of pre-proposals:
- July 21, 2023 12:00 noon CEST – Call Secretariat
- July 21, 2023 2:00 pm CEST – FWF
Deadline for submission of full proposals:
- December 15, 2023 12:00 noon CET – Call Secretariat
- December 15, 2023 2:00 pm CET – FWF
Austrian Science Fund (FWF)